Inhibrx, Inc. (INBX)

Market Cap	852.27M
Revenue (ttm)	2.19M
Net Income (ttm)	-145.23M
Shares Out	43.57M
EPS (ttm)	-3.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	292,268
Open	19.27
Previous Close	19.04
Day's Range	19.01 - 19.94
52-Week Range	7.67 - 34.72
Beta	2.97
Analysts	Buy
Price Target	49.16 (+151.33%)
Earnings Date	May 8, 2023

About INBX

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 106
• Stock Exchange: NASDAQ
• Ticker Symbol: INBX

Financial Performance

In 2022, Inhibrx's revenue was $2.19 million, a decrease of -69.69% compared to the previous year's $7.23 million. Losses were -$145.23 million, 77.6% more than in 2021.

Analyst Forecast

According to 12 analysts, the average rating for INBX stock is "Buy." The 12-month stock price forecast is $49.16, which is an increase of 151.33% from the latest price.

Price Target

$49.16

(151.33% upside)

Analyst Consensus: Buy